Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical validation of chromogenic substrate assay in hemophilia A patients without inhibitors receiving emicizumab
jRCTs031210222Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of emicizumab and Factor VIII in hemophilia A (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Collective correlation and variability of emicizumab blood concentration and factor VIII activity in groups A and C. Started Aug 2021; status: active, not recruiting.
02
Drugs
emicizumabFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCTs031210222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210222.